Johnson & Johnson
JNJNext catalyst
Nipocalimab
Arthritis, Rheumatoid
Get an email about JNJ's next catalysts
Track Johnson & Johnson (JNJ) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 6 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
7 upcoming, 1 past
Nipocalimab Phase 3 Est. Readout
Estimated primary completion for Nipocalimab trial (NCT05327114) in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Topline data typically follows completion by weeks to months.
SourceNipocalimab Phase 3 Est. Readout (DAFFODIL)
Estimated primary completion for Nipocalimab trial (NCT06533098) in Thrombocytopenia, Neonatal Alloimmune. Topline data typically follows completion by weeks to months.
SourceAmivantamab IV Phase 2 Est. Readout (OrigAMI-1)
Estimated primary completion for Amivantamab IV trial (NCT05379595) in Advanced or Metastatic Colorectal Cancer. Topline data typically follows completion by weeks to months.
SourceDaratumumab Phase 3 Est. Readout (MonumenTAL-3)
Primary completion for Daratumumab trial (NCT05455320) in Relapsed or Refractory Multiple Myeloma
SourceTeclistamab Phase 2 Est. Readout
Estimated primary completion for Teclistamab trial (NCT05972135) in Multiple Myeloma. Topline data typically follows completion by weeks to months.
SourceAmivantamab Phase 2 Est. Readout (PALOMA-2)
Estimated primary completion for Amivantamab trial (NCT05498428) in Carcinoma, Non-small-Cell Lung. Topline data typically follows completion by weeks to months.
SourceNipocalimab Phase 3 Est. Readout (EPIC)
Estimated primary completion for Nipocalimab trial (NCT07217587) in Myasthenia Gravis. Topline data typically follows completion by weeks to months.
SourceHow JNJ's past catalysts played out
Market Overview
Stock performance and key metrics
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.
WebsiteAbiraterone acetate
Prostate Neoplasms
Lazertinib
Carcinoma, Non-Small-Cell Lung
PP6M
Schizophrenia
Etravirine
HIV Infections
tapentadol (CG5503) Immediate Release (IR)
Low Back Pain
Tapentadol (CG5503)
Arthralgia
CONCERTA (OROS methylphenidate hydrochloride)
Attention Deficit Disorder With Hyperactivity
OROS hydromorphone HCl
Pain
Peginterferon-alpha (PegIFNα-2a)
Hepatitis C, Chronic
MVA-BN-Filo
Hemorrhagic Fever, Ebola
Decitabine
Leukemia, Myeloid, Acute
Genetic: AAV5-hRKp.RPGR Intermediate Dose
X-Linked Retinitis Pigmentosa
Ad26.Mos4.HIV
Healthy
Icotrokinra
Crohn Disease
Remifentanil
Anesthesia
Pegylated interferon alfa-2a
Chronic Hepatitis C Virus (HCV) Infection
Guselkumab dose 1
Hidradenitis Suppurativa
Aticaprant
Depressive Disorder, Major
Milvexian
Acute Coronary Syndrome
Fentanyl 1-day transdermal patch (Titration Phase)
Pain
ER OROS paliperidone
Schizophrenia
Efgartigimod
Myasthenia Gravis
Erdafitinib
Advanced Solid Tumor
5-Flurouracil
Squamous Cell Carcinoma of Head and Neck
Group 2 ustekinumab
Crohn's Disease
ExPEC9V
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
NUCYNTA
Pain
Paliperidone palmitate (R092670)
Schizophrenia
paliperidone palmitate injection
Schizophrenia
TAR-210
Non-Muscle Invasive Bladder Neoplasms
Vinflunine
Urothelial Cancer
Guselkumab Dose 2
Colitis, Ulcerative
Ustekinumab IV
Colitis, Ulcerative
PP3M eq
Schizophrenia
Ad26.ZEBOV
Ebola Virus Disease
Bendamustine hydrochloride
Chronic Lymphocytic Leukemia
R331333 (referred to as JNS024 ER or CG5503)
Pain
Genetic: AAV5-hRKp.RPGR
X-Linked Retinitis Pigmentosa
Efavirenz
Human Immunodeficiency Virus-type 1 Infection
Pegylated interferon alfa-2a (PegIFNα-2a)
Hepatitis C, Chronic
Golimumab
Arthritis, Juvenile
Risankizumab
Crohn Disease
Nipocalimab
Arthritis, Rheumatoid
Rabeprazole sodium
Gastroesophageal Reflux
Telaprevir
Hepatitis C, Chronic
DRV + COBI + FTC + TAF FDC
HIV-1
Pegylated interferon alpha-2a
Hepatitis C Virus Genotype-1
Durogesic® (fentanyl transdermal drug delivery system)
Chronic Pain
Paliperidone ER OROS®
Schizophrenia
Canagliflozin
Diabetes Mellitus, Type 2
galantamine ER
Alzheimer's Disease
Ad26.ZEBOV 5*10^10 viral particles (vp)
Healthy
Intravenous immunoglobulins (IVIG)
Thrombocytopenia, Neonatal Alloimmune
methylphenidate
Depressive Disorder, Major
Sirukumab
Arthritis, Rheumatoid
Daratumumab IV
Multiple Myeloma
Paliperidone extended release (ER)
Schizophrenia
Ad26.RSV.PreF-based Vaccine
Respiratory Syncytial Virus Prevention
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
Respiratory Syncytial Viruses
D/C/F/TAF
Human Immunodeficiency Virus Type 1
Nesiritide
Heart Decompensation
Fumaric Acid Esters
Psoriasis
Temsirolimus
Mantle Cell Lymphoma
Sofosbuvir
Chronic Hepatitis C
Epo-alpha
Resuscitation
Tapentadol (CG5503) Extended Release (ER)
Pain
Rivaroxaban (Xarelto, BAY59-7939)
Venous Thromboembolism
Morphine
Hysterectomy
oxycodone
Osteoarthritis, Knee
Risperidone, long-acting injectable
Schizophrenia
risperidone; quetiapine
Bipolar Disorder
topiramate, propranolol
Migraine
Enoxaparin
Venous Thromboembolism
VELCADE
Diffuse Large B-Cell Lymphoma
CG5503 IR
Bunionectomy
Acetaminophen
Post Operative Analgesia
oxycodone CR
Joint Diseases
F#13418-158 Eye Drops
Ophthalmic Solutions
tramadol, acetaminophen
Diabetic Neuropathies
risperidone oral tablets
Anxiety Disorders
Risperidone long-acting injectable
Schizophrenia
Bortezomib + Rituximab
Non-Hodgkin's Lymphoma
Epoetin alfa once every two weeks
Anemia
Epoetin alfa once weekly
Anemia
Tapentadol ER
Pain
recombinant human erythropoietin alfa
Infarction, Middle Cerebral Artery
Cyclophosphamide
Mantle Cell Lymphoma
Micronized 17B-estradiol
Atherosclerosis
levofloxacin; amoxicillin/clavulanate
Otitis Media
ICI35,868 (Diprivan) + EES0000645/A (SDS)
Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy
VELCADE Administered by subcutaneous injection
Multiple Myeloma
Risperidone, oral tablets
Bipolar Disorders
levofloxacin, azithromycin, amoxicillin/clavulanate
Bronchitis
ICI35,868 (Diprivan)
Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy
Tapentadol IR (CG5503)
Joint Diseases
Conventional Antiarrhythmic Drug Therapy
Atrial Fibrillation
Tapentadol ER (CG5503)
Joint Diseases
Test acetaminophen
Post-operative Dental Pain
CG 5503;tapentadol
Osteoarthritis
tapentadol (CG5503) ER
Low Back Pain
levofloxacin
Pneumonia
Rivaroxaban
Atrial Fibrillation
tapentadol (CG5503) Immediate Release IR
Low Back Pain
Acetaminophen/Naproxen Sodium Fixed Combination
Pain
Paliperidone extended-release
Bipolar Disorder
Risperdal Consta
Bipolar Disorder
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
Multiple Myeloma
paliperidone ER Oros
Schizophrenia
Gemcitabine with R115777
Pancreatic Neoplasms
Mebendazole
Healthy Volunteers
Dapoxetine
Erectile Dysfunction
F# 13418-148 Eye Drops
Ophthalmic Solutions
Rivaroxaban 2.5 mg
Acute Coronary Syndrome
Paliperidone ER
Schizophrenia
topiramate
Essential Tremor
doripenem
Pneumonia
norelgestromin + ethinyl estradiol
Contraception
Tapentadol extended release (ER)
Diabetic Peripheral Neuropathy
Thalidomide
Multiple Myeloma
CG5503 IR;tapentadol
Arthralgia
Topiramate; Carbamazepine; Valproate
Epilepsy
levofloxacin; imipenem/cilastitin
Nosocomial Pneumonia
Pancrease MT 10.5, or MT 21
Exocrine Pancreatic Insufficiency
Colloidal Oatmeal Cream
Eczema
ivermectin
Lice Infestations
Paliperidone palmitate eq
Schizophrenia
JNJ-90301900 (NBTXR3)
Locally Advanced Head and Neck Squamous Cell Carcinoma
norelgestromin + ethinyl estradiol; mercilon
Contraception
Extended-release galantamine hydrobromide
Schizophrenia
Test naproxen sodium tablet
Post-operative Dental Pain
galantamine
Alzheimer's Disease
Minoxidil Topical Foam
Androgenetic Alopecia
Imonogas
Functional Dyspepsia
rabeprazole
Gastroesophageal Reflux Disease (GERD)
galantamine hydrobromide
Alzheimer Disease
Hydromorphone HCl
Pain
topiramate, phenytoin
Epilepsy
Paliperidone palmitate
Schizophrenia
norelgestromin + ethinyl estradiol; triphasil
Contraception
doripenum
Urinary Tract Infections
acetaminophen extended release
Osteoarthritis
CG5503
Diabetic Neuropathy
Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)
Chronic Pain
CG5503 IR; tapentadol
Osteoarthritis
naproxen
Osteoarthritis, Hip
minoxidil
Androgenetic Alopecia
PDE5I (phosphodiesterase-5 inhibitor)
Erectile Dysfunction
Extended Release OROS® Paliperidone
Schizophrenia
acetaminophen Tablet
Post Operative Dental Pain
Paliperidone
Schizophrenia
Epoetin alfa 3 times weekly/once weekly
Anemia
Tipifarnib;Zarnestra; R115777
Acute Myeloid Leukemia
epoetin alfa
Chronic Kidney Disease
Prucalopride
Constipation
Tapentadol Extended Release
Tumor
Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell
TAR-200
Non-Muscle Invasive Bladder Neoplasms
Levetiracetam
Epilepsy
Cilta-cel
Multiple Myeloma
Talquetamab
Multiple Myeloma
TMC435
Hepatitis C
JNJ-77242113
Plaque Psoriasis
Simeprevir
Hepatitis C Virus Infection
Fentanyl
Postherpetic Neuralgia
No treatment
Hepatitis C
JNJ-63723283
Multiple Myeloma
Guselkumab
Psoriasis
Daratumumab
Multiple Myeloma
Ad26.COV2.S
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Macitentan
Pulmonary Arterial Hypertension
Fulranumab
Osteoarthritis
Rilpivirine
HIV-1
Amivantamab
Carcinoma, Non-Small-Cell Lung
Seltorexant
Depressive Disorder, Major
Ustekinumab
Crohn Disease
Teclistamab
Multiple Myeloma
R228060
Major Depressive Disorder
JNJ-40411813
Major Depressive Disorder
Experimental Product Colloidal Oatmeal Balm
Atopic Dermatitis
Antipsychotic medication
Schizophrenia
JNJ-73763989
Hepatitis B, Chronic
JNJ-90301900
Carcinoma, Non-Small-Cell Lung
Acetaminophen/naproxen sodium Dose C
Pain
JNJ16269110
Diabetes Mellitus, Type 2
Pseudoephedrine
Allergic Rhinitis
ibuprofen; pseudoephedrine HCl
Enuresis
Ad26.ZEBOV vaccine
Ebola Virus Disease
NNC0142-0002
Inflammation
RSV Vaccine
Healthy
cholecalciferol
Prostate Cancer
Erdafitinib Intravesical Delivery System
Non-Muscle Invasive Bladder Neoplasms
Tapentadol
Pain
Ad26.RSV.preF (1*10^11 vp)
Respiratory Syncytial Viruses
tapentadol HCl
Pain
VELCADE (bortezomib)
Multiple Myeloma
ET743
Breast Neoplasms
JNJ-37822681
Schizophrenia
JNJ-63623872
Influenza A Virus
AL-335
Hepatitis C, Chronic
Apalutamide
Salivary Gland Neoplasms
Acetaminophen/naproxen sodium Dose D
Pain
R092670
Schizophrenia
Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Carcinoma, Non-Small-Cell Lung
Olomorasib
Carcinoma, Non-Small-Cell Lung
JNJ-41443532
Diabetes Mellitus, Type 2
VX-787
Influenza A
JNJ-39588146/min
Heart Failure
tipifarnib (R115777)
Leukemia, Nonlymphocytic, Acute
JNJ39758979
Asthma
Ad26.RSV.preF
Respiratory Syncytial Virus
Ketoconazole
Neoplasm Metastases
Ad26.Mos.HIV
Healthy
Imipenem/cilastatin
Pneumonia, Ventilator-Associated
JNJ-31001074
Attention Deficit Hyperactivity Disorder
Fluarix
Healthy
JNJ-39588146 5, 15, or/min
Heart Failure
Alimta
Non-Small Cell Lung Cancer
JNJ 40929837
Asthma
Daratumumab Injection
Plasma Cell Disorder
R209130
Schizophrenia
Cetrelimab
Urinary Bladder Neoplasms
JNJ-42847922
Depressive Disorder, Major
Acetaminophen/naproxen sodium Dose A
Pain
R256918
Obesity
Atazanavir (ATV)
HIV Infections
ZARNESTRA, tipifarnib, R115777
Acute Myeloid Leukemia
ExPEC4V (4 : 4 : 4 : 4)
Healthy
TMC207 (bedaquiline)
Tuberculosis, Multidrug-Resistant
JNJ-17166864
Allergic Rhinitis
Acetaminophen (ACE)
Dental Pain
JNJ 49095397
Chronic Obstructive Pulmonary Disease
Escitalopram
Major Depressive Disorder
JNJ-64565111 Dose Level 1
Obesity and Diabetes Mellitus, Type 2
CNTO 1959
Palmoplantaris Pustulosis
Acetaminophen/naproxen sodium Dose B
Pain
PROCRIT (Epoetin alfa)
Anemia
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Multiple Myeloma
Nesiritide (1+0.01)
Heart Failure, Congestive
Acetaminophen/naproxen sodium Dose E
Pain
Oral Dexamethasone
Multiple Myeloma
Siltuximab
Multicentric Castleman's Disease
Blink® Tears eye drops in a multidose bottle
Visual Acuity
Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Carcinoma, Non-Small-Cell Lung
T2-18C3 therapeutic antibody
Type 2 Diabetes
Xarelto (Rivaroxaban, BAY59-7939)
Venous Thromboembolism
JNJ-26489112
Photosensitive Epilepsy
naproxen sodium with acetaminophen
Pain
Atomoxetine
Attention Deficit Hyperactivity Disorder
Investigational Lubricating Eye Drop in a Novelia® bottle
Dry Eye
JNJ-39220675
Allergic Rhinitis
JNJ-40346527
Arthritis, Rheumatoid
Yondelis
Liposarcoma
JNJ-64304500
Crohn Disease
NNC 0142-0000-0002
Inflammation
JNJ-39393406
Depression
Amivantamab IV
Advanced or Metastatic Colorectal Cancer
Glucocorticoids
Myositis
JNJ-81201887
Geographic Atrophy
CNTO 2476 3.0 x 10^5 cells
Visual Acuity
Canagliflozin (JNJ-28431754)
Diabetes Mellitus, Type II
RWJ-445380
Rheumatoid Arthritis
R115777
Glioblastoma Multiforme
bortezomib, dexamethasone, thalidomide, and cyclophosphamide
Multiple Myeloma
sIPV
Healthy
bortezomib, dexamethasone, and thalidomide
Multiple Myeloma
JNJ-18038683
Major Depressive Disorder
MVA-Mosaic
Human Immunodeficiency Virus
Daratumumab (Part 1)
Multiple Myeloma
JNJ-53718678
Respiratory Syncytial Virus Infections
Abiraterone
Prostate Cancer
Capmatinib
Carcinoma, Non-Small-Cell Lung
JNJ-42165279
Depressive Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Abiraterone acetate | Phase 3 | Prostate Neoplasms | - | - |
Lazertinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
PP6M | Phase 3 | Schizophrenia | - | - |
Etravirine | Phase 3 | HIV Infections | - | - |
tapentadol (CG5503) Immediate Release (IR) | Phase 3 | Low Back Pain | - | - |
Tapentadol (CG5503) | Phase 3 | Arthralgia | - | - |
CONCERTA (OROS methylphenidate hydrochloride) | Phase 3 | Attention Deficit Disorder With Hyperactivity | - | - |
OROS hydromorphone HCl | Phase 3 | Pain | - | - |
Peginterferon-alpha (PegIFNα-2a) | Phase 3 | Hepatitis C, Chronic | - | - |
MVA-BN-Filo | Phase 3 | Hemorrhagic Fever, Ebola | - | - |
Decitabine | Phase 3 | Leukemia, Myeloid, Acute | - | - |
Genetic: AAV5-hRKp.RPGR Intermediate Dose | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
Ad26.Mos4.HIV | Phase 3 | Healthy | - | - |
Icotrokinra | Phase 3 | Crohn Disease | - | - |
Remifentanil | Phase 3 | Anesthesia | - | - |
Pegylated interferon alfa-2a | Phase 3 | Chronic Hepatitis C Virus (HCV) Infection | - | - |
Guselkumab dose 1 | Phase 3 | Hidradenitis Suppurativa | - | - |
Aticaprant | Phase 3 | Depressive Disorder, Major | - | - |
Milvexian | Phase 3 | Acute Coronary Syndrome | - | - |
Fentanyl 1-day transdermal patch (Titration Phase) | Phase 3 | Pain | - | - |
ER OROS paliperidone | Phase 3 | Schizophrenia | - | - |
Efgartigimod | Phase 3 | Myasthenia Gravis | - | - |
Erdafitinib | Phase 3 | Advanced Solid Tumor | - | - |
5-Flurouracil | Phase 3 | Squamous Cell Carcinoma of Head and Neck | - | - |
Group 2 ustekinumab | Phase 3 | Crohn's Disease | - | - |
ExPEC9V | Phase 3 | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | - | - |
NUCYNTA | Phase 3 | Pain | - | - |
Paliperidone palmitate (R092670) | Phase 3 | Schizophrenia | - | - |
paliperidone palmitate injection | Phase 3 | Schizophrenia | - | - |
TAR-210 | Phase 3 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Vinflunine | Phase 3 | Urothelial Cancer | - | - |
Guselkumab Dose 2 | Phase 3 | Colitis, Ulcerative | - | - |
Ustekinumab IV | Phase 3 | Colitis, Ulcerative | - | - |
PP3M eq | Phase 3 | Schizophrenia | - | - |
Ad26.ZEBOV | Phase 3 | Ebola Virus Disease | - | - |
Bendamustine hydrochloride | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
R331333 (referred to as JNS024 ER or CG5503) | Phase 3 | Pain | - | - |
Genetic: AAV5-hRKp.RPGR | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
Efavirenz | Phase 3 | Human Immunodeficiency Virus-type 1 Infection | - | - |
Pegylated interferon alfa-2a (PegIFNα-2a) | Phase 3 | Hepatitis C, Chronic | - | - |
Golimumab | Phase 3 | Arthritis, Juvenile | - | - |
Risankizumab | Phase 3 | Crohn Disease | - | - |
Nipocalimab | Phase 3 | Arthritis, Rheumatoid | - | - |
Rabeprazole sodium | Phase 3 | Gastroesophageal Reflux | - | |
Telaprevir | Phase 3 | Hepatitis C, Chronic | - | - |
DRV + COBI + FTC + TAF FDC | Phase 3 | HIV-1 | - | - |
Pegylated interferon alpha-2a | Phase 3 | Hepatitis C Virus Genotype-1 | - | - |
Durogesic® (fentanyl transdermal drug delivery system) | Phase 3 | Chronic Pain | - | - |
Paliperidone ER OROS® | Phase 3 | Schizophrenia | - | - |
Canagliflozin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
galantamine ER | Phase 3 | Alzheimer's Disease | - | - |
Ad26.ZEBOV 5*10^10 viral particles (vp) | Phase 3 | Healthy | - | - |
Intravenous immunoglobulins (IVIG) | Phase 3 | Thrombocytopenia, Neonatal Alloimmune | - | - |
methylphenidate | Phase 3 | Depressive Disorder, Major | - | - |
Sirukumab | Phase 3 | Arthritis, Rheumatoid | - | - |
Daratumumab IV | Phase 3 | Multiple Myeloma | - | - |
Paliperidone extended release (ER) | Phase 3 | Schizophrenia | - | - |
Ad26.RSV.PreF-based Vaccine | Phase 3 | Respiratory Syncytial Virus Prevention | - | - |
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF | Phase 3 | Respiratory Syncytial Viruses | - | - |
D/C/F/TAF | Phase 3 | Human Immunodeficiency Virus Type 1 | - | - |
Nesiritide | Phase 3 | Heart Decompensation | - | - |
Fumaric Acid Esters | Phase 3 | Psoriasis | - | - |
Temsirolimus | Phase 3 | Mantle Cell Lymphoma | - | - |
Sofosbuvir | Phase 3 | Chronic Hepatitis C | - | - |
Epo-alpha | Phase 3 | Resuscitation | - | - |
Tapentadol (CG5503) Extended Release (ER) | Phase 3 | Pain | - | - |
Rivaroxaban (Xarelto, BAY59-7939) | Phase 3 | Venous Thromboembolism | - | - |
Morphine | Phase 3 | Hysterectomy | - | - |
oxycodone | Phase 3 | Osteoarthritis, Knee | - | - |
Risperidone, long-acting injectable | Phase 3 | Schizophrenia | - | - |
risperidone; quetiapine | Phase 3 | Bipolar Disorder | - | - |
topiramate, propranolol | Phase 3 | Migraine | - | - |
Enoxaparin | Phase 3 | Venous Thromboembolism | - | - |
VELCADE | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
CG5503 IR | Phase 3 | Bunionectomy | - | - |
Acetaminophen | Phase 3 | Post Operative Analgesia | - | - |
oxycodone CR | Phase 3 | Joint Diseases | - | - |
F#13418-158 Eye Drops | Phase 3 | Ophthalmic Solutions | - | - |
tramadol, acetaminophen | Phase 3 | Diabetic Neuropathies | - | - |
risperidone oral tablets | Phase 3 | Anxiety Disorders | - | - |
Risperidone long-acting injectable | Phase 3 | Schizophrenia | - | - |
Bortezomib + Rituximab | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
Epoetin alfa once every two weeks | Phase 3 | Anemia | - | - |
Epoetin alfa once weekly | Phase 3 | Anemia | - | - |
Tapentadol ER | Phase 3 | Pain | - | - |
recombinant human erythropoietin alfa | Phase 3 | Infarction, Middle Cerebral Artery | - | - |
Cyclophosphamide | Phase 3 | Mantle Cell Lymphoma | - | - |
Micronized 17B-estradiol | Phase 3 | Atherosclerosis | - | - |
levofloxacin; amoxicillin/clavulanate | Phase 3 | Otitis Media | - | - |
ICI35,868 (Diprivan) + EES0000645/A (SDS) | Phase 3 | Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy | - | - |
VELCADE Administered by subcutaneous injection | Phase 3 | Multiple Myeloma | - | - |
Risperidone, oral tablets | Phase 3 | Bipolar Disorders | - | - |
levofloxacin, azithromycin, amoxicillin/clavulanate | Phase 3 | Bronchitis | - | - |
ICI35,868 (Diprivan) | Phase 3 | Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy | - | - |
Tapentadol IR (CG5503) | Phase 3 | Joint Diseases | - | - |
Conventional Antiarrhythmic Drug Therapy | Phase 3 | Atrial Fibrillation | - | - |
Tapentadol ER (CG5503) | Phase 3 | Joint Diseases | - | - |
Test acetaminophen | Phase 3 | Post-operative Dental Pain | - | Patent 2032 |
CG 5503;tapentadol | Phase 3 | Osteoarthritis | - | - |
tapentadol (CG5503) ER | Phase 3 | Low Back Pain | - | - |
levofloxacin | Phase 3 | Pneumonia | - | |
Rivaroxaban | Phase 3 | Atrial Fibrillation | - | Patent 2044 |
tapentadol (CG5503) Immediate Release IR | Phase 3 | Low Back Pain | - | - |
Acetaminophen/Naproxen Sodium Fixed Combination | Phase 3 | Pain | - | - |
Paliperidone extended-release | Phase 3 | Bipolar Disorder | - | - |
Risperdal Consta | Phase 3 | Bipolar Disorder | - | - |
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) | Phase 3 | Multiple Myeloma | - | - |
paliperidone ER Oros | Phase 3 | Schizophrenia | - | |
Gemcitabine with R115777 | Phase 3 | Pancreatic Neoplasms | - | - |
Mebendazole | Phase 3 | Healthy Volunteers | - | |
Dapoxetine | Phase 3 | Erectile Dysfunction | - | - |
F# 13418-148 Eye Drops | Phase 3 | Ophthalmic Solutions | - | - |
Rivaroxaban 2.5 mg | Phase 3 | Acute Coronary Syndrome | - | Patent 2044 |
Paliperidone ER | Phase 3 | Schizophrenia | - | |
topiramate | Phase 3 | Essential Tremor | - | Patent 2040 |
doripenem | Phase 3 | Pneumonia | - | |
norelgestromin + ethinyl estradiol | Phase 3 | Contraception | - | - |
Tapentadol extended release (ER) | Phase 3 | Diabetic Peripheral Neuropathy | - | - |
Thalidomide | Phase 3 | Multiple Myeloma | - | - |
CG5503 IR;tapentadol | Phase 3 | Arthralgia | - | - |
Topiramate; Carbamazepine; Valproate | Phase 3 | Epilepsy | - | - |
levofloxacin; imipenem/cilastitin | Phase 3 | Nosocomial Pneumonia | - | - |
Pancrease MT 10.5, or MT 21 | Phase 3 | Exocrine Pancreatic Insufficiency | - | - |
Colloidal Oatmeal Cream | Phase 3 | Eczema | - | - |
ivermectin | Phase 3 | Lice Infestations | - | - |
Paliperidone palmitate eq | Phase 3 | Schizophrenia | - | - |
JNJ-90301900 (NBTXR3) | Phase 3 | Locally Advanced Head and Neck Squamous Cell Carcinoma | - | - |
norelgestromin + ethinyl estradiol; mercilon | Phase 3 | Contraception | - | - |
Extended-release galantamine hydrobromide | Phase 3 | Schizophrenia | - | - |
Test naproxen sodium tablet | Phase 3 | Post-operative Dental Pain | - | - |
galantamine | Phase 3 | Alzheimer's Disease | - | - |
Minoxidil Topical Foam | Phase 3 | Androgenetic Alopecia | - | - |
Imonogas | Phase 3 | Functional Dyspepsia | - | - |
rabeprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
galantamine hydrobromide | Phase 3 | Alzheimer Disease | - | - |
Hydromorphone HCl | Phase 3 | Pain | - | - |
topiramate, phenytoin | Phase 3 | Epilepsy | - | - |
Paliperidone palmitate | Phase 3 | Schizophrenia | - | - |
norelgestromin + ethinyl estradiol; triphasil | Phase 3 | Contraception | - | - |
doripenum | Phase 3 | Urinary Tract Infections | - | - |
acetaminophen extended release | Phase 3 | Osteoarthritis | - | - |
CG5503 | Phase 3 | Diabetic Neuropathy | - | - |
Duragesic® (fentanyl) Therapeutic Transdermal System (TTS) | Phase 3 | Chronic Pain | - | - |
CG5503 IR; tapentadol | Phase 3 | Osteoarthritis | - | - |
naproxen | Phase 3 | Osteoarthritis, Hip | - | - |
minoxidil | Phase 3 | Androgenetic Alopecia | - | - |
PDE5I (phosphodiesterase-5 inhibitor) | Phase 3 | Erectile Dysfunction | - | - |
Extended Release OROS® Paliperidone | Phase 3 | Schizophrenia | - | - |
acetaminophen Tablet | Phase 3 | Post Operative Dental Pain | - | - |
Paliperidone | Phase 3 | Schizophrenia | - | - |
Epoetin alfa 3 times weekly/once weekly | Phase 3 | Anemia | - | - |
Tipifarnib;Zarnestra; R115777 | Phase 3 | Acute Myeloid Leukemia | - | - |
epoetin alfa | Phase 3 | Chronic Kidney Disease | - | - |
Prucalopride | Phase 3 | Constipation | - | - |
Tapentadol Extended Release | Phase 3 | Tumor | - | - |
Ibrutinib | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
TAR-200 | Phase 3 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Levetiracetam | Phase 3 | Epilepsy | - | - |
Cilta-cel | Phase 3 | Multiple Myeloma | - | - |
Talquetamab | Phase 3 | Multiple Myeloma | - | - |
TMC435 | Phase 3 | Hepatitis C | - | - |
JNJ-77242113 | Phase 3 | Plaque Psoriasis | - | - |
Simeprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
Fentanyl | Phase 3 | Postherpetic Neuralgia | - | - |
No treatment | Phase 3 | Hepatitis C | - | - |
JNJ-63723283 | Phase 3 | Multiple Myeloma | - | - |
Guselkumab | Phase 3 | Psoriasis | - | - |
Daratumumab | Phase 3 | Multiple Myeloma | - | - |
Ad26.COV2.S | Phase 3 | Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol | - | - |
Macitentan | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Fulranumab | Phase 3 | Osteoarthritis | - | - |
Rilpivirine | Phase 3 | HIV-1 | - | - |
Amivantamab | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Seltorexant | Phase 3 | Depressive Disorder, Major | - | - |
Ustekinumab | Phase 3 | Crohn Disease | - | - |
Teclistamab | Phase 3 | Multiple Myeloma | - | - |
R228060 | Phase 2 | Major Depressive Disorder | - | - |
JNJ-40411813 | Phase 2 | Major Depressive Disorder | - | - |
Experimental Product Colloidal Oatmeal Balm | Phase 2 | Atopic Dermatitis | - | - |
Antipsychotic medication | Phase 2 | Schizophrenia | - | - |
JNJ-73763989 | Phase 2 | Hepatitis B, Chronic | - | - |
JNJ-90301900 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Acetaminophen/naproxen sodium Dose C | Phase 2 | Pain | - | - |
JNJ16269110 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Pseudoephedrine | Phase 2 | Allergic Rhinitis | - | - |
ibuprofen; pseudoephedrine HCl | Phase 2 | Enuresis | - | - |
Ad26.ZEBOV vaccine | Phase 2 | Ebola Virus Disease | - | - |
NNC0142-0002 | Phase 2 | Inflammation | - | - |
RSV Vaccine | Phase 2 | Healthy | - | - |
cholecalciferol | Phase 2 | Prostate Cancer | - | - |
Erdafitinib Intravesical Delivery System | Phase 2 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Tapentadol | Phase 2 | Pain | - | - |
Ad26.RSV.preF (1*10^11 vp) | Phase 2 | Respiratory Syncytial Viruses | - | - |
tapentadol HCl | Phase 2 | Pain | - | - |
VELCADE (bortezomib) | Phase 2 | Multiple Myeloma | - | - |
ET743 | Phase 2 | Breast Neoplasms | - | - |
JNJ-37822681 | Phase 2 | Schizophrenia | - | - |
JNJ-63623872 | Phase 2 | Influenza A Virus | - | - |
AL-335 | Phase 2 | Hepatitis C, Chronic | - | - |
Apalutamide | Phase 2 | Salivary Gland Neoplasms | - | - |
Acetaminophen/naproxen sodium Dose D | Phase 2 | Pain | - | - |
R092670 | Phase 2 | Schizophrenia | - | - |
Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Olomorasib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
JNJ-41443532 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
VX-787 | Phase 2 | Influenza A | - | - |
JNJ-39588146/min | Phase 2 | Heart Failure | - | - |
tipifarnib (R115777) | Phase 2 | Leukemia, Nonlymphocytic, Acute | - | - |
JNJ39758979 | Phase 2 | Asthma | - | - |
Ad26.RSV.preF | Phase 2 | Respiratory Syncytial Virus | - | - |
Ketoconazole | Phase 2 | Neoplasm Metastases | - | - |
Ad26.Mos.HIV | Phase 2 | Healthy | - | - |
Imipenem/cilastatin | Phase 2 | Pneumonia, Ventilator-Associated | - | - |
JNJ-31001074 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
Fluarix | Phase 2 | Healthy | - | - |
JNJ-39588146 5, 15, or/min | Phase 2 | Heart Failure | - | - |
Alimta | Phase 2 | Non-Small Cell Lung Cancer | - | - |
JNJ 40929837 | Phase 2 | Asthma | - | - |
Daratumumab Injection | Phase 2 | Plasma Cell Disorder | - | - |
R209130 | Phase 2 | Schizophrenia | - | - |
Cetrelimab | Phase 2 | Urinary Bladder Neoplasms | - | - |
JNJ-42847922 | Phase 2 | Depressive Disorder, Major | - | - |
Acetaminophen/naproxen sodium Dose A | Phase 2 | Pain | - | - |
R256918 | Phase 2 | Obesity | - | - |
Atazanavir (ATV) | Phase 2 | HIV Infections | - | - |
ZARNESTRA, tipifarnib, R115777 | Phase 2 | Acute Myeloid Leukemia | - | - |
ExPEC4V (4 : 4 : 4 : 4) | Phase 2 | Healthy | - | - |
TMC207 (bedaquiline) | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
JNJ-17166864 | Phase 2 | Allergic Rhinitis | - | - |
Acetaminophen (ACE) | Phase 2 | Dental Pain | - | - |
JNJ 49095397 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Escitalopram | Phase 2 | Major Depressive Disorder | - | - |
JNJ-64565111 Dose Level 1 | Phase 2 | Obesity and Diabetes Mellitus, Type 2 | - | - |
CNTO 1959 | Phase 2 | Palmoplantaris Pustulosis | - | - |
Acetaminophen/naproxen sodium Dose B | Phase 2 | Pain | - | - |
PROCRIT (Epoetin alfa) | Phase 2 | Anemia | - | - |
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) | Phase 2 | Multiple Myeloma | - | - |
Nesiritide (1+0.01) | Phase 2 | Heart Failure, Congestive | - | - |
Acetaminophen/naproxen sodium Dose E | Phase 2 | Pain | - | - |
Oral Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
Siltuximab | Phase 2 | Multicentric Castleman's Disease | - | - |
Blink® Tears eye drops in a multidose bottle | Phase 2 | Visual Acuity | - | - |
Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
T2-18C3 therapeutic antibody | Phase 2 | Type 2 Diabetes | - | - |
Xarelto (Rivaroxaban, BAY59-7939) | Phase 2 | Venous Thromboembolism | - | - |
JNJ-26489112 | Phase 2 | Photosensitive Epilepsy | - | - |
naproxen sodium with acetaminophen | Phase 2 | Pain | - | - |
Atomoxetine | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
Investigational Lubricating Eye Drop in a Novelia® bottle | Phase 2 | Dry Eye | - | - |
JNJ-39220675 | Phase 2 | Allergic Rhinitis | - | - |
JNJ-40346527 | Phase 2 | Arthritis, Rheumatoid | - | - |
Yondelis | Phase 2 | Liposarcoma | - | - |
JNJ-64304500 | Phase 2 | Crohn Disease | - | - |
NNC 0142-0000-0002 | Phase 2 | Inflammation | - | - |
JNJ-39393406 | Phase 2 | Depression | - | - |
Amivantamab IV | Phase 2 | Advanced or Metastatic Colorectal Cancer | - | - |
Glucocorticoids | Phase 2 | Myositis | - | - |
JNJ-81201887 | Phase 2 | Geographic Atrophy | - | - |
CNTO 2476 3.0 x 10^5 cells | Phase 2 | Visual Acuity | - | - |
Canagliflozin (JNJ-28431754) | Phase 2 | Diabetes Mellitus, Type II | - | - |
RWJ-445380 | Phase 2 | Rheumatoid Arthritis | - | - |
R115777 | Phase 2 | Glioblastoma Multiforme | - | - |
bortezomib, dexamethasone, thalidomide, and cyclophosphamide | Phase 2 | Multiple Myeloma | - | - |
sIPV | Phase 2 | Healthy | - | - |
bortezomib, dexamethasone, and thalidomide | Phase 2 | Multiple Myeloma | - | - |
JNJ-18038683 | Phase 2 | Major Depressive Disorder | - | - |
MVA-Mosaic | Phase 2 | Human Immunodeficiency Virus | - | - |
Daratumumab (Part 1) | Phase 2 | Multiple Myeloma | - | - |
JNJ-53718678 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
Abiraterone | Phase 2 | Prostate Cancer | - | - |
Capmatinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
JNJ-42165279 | Phase 2 | Depressive Disorder | - | - |
Schizophrenia
4 drugs in this indication
Bipolar Disorder
3 drugs in this indication
Pain
2 drugs in this indication
Multiple Myeloma
2 drugs in this indication
Pneumonia
2 drugs in this indication
Diabetes Mellitus, Type 2
2 drugs in this indication
Low Back Pain
2 drugs in this indication
Atopic Dermatitis
2 drugs in this indication
Heart Failure
2 drugs in this indication
relapsed or refractory multiple myeloma
2 drugs in this indication
Pain relief
2 drugs in this indication
relapsed/refractory multiple myeloma
2 drugs in this indication
Major Depressive Disorder
1 drug in this indication
Ophthalmic Solutions
1 drug in this indication
Acute Coronary Syndrome
1 drug in this indication
Contraception
1 drug in this indication
Post-operative Dental Pain
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Healthy Volunteers
1 drug in this indication
Osteoarthritis
1 drug in this indication
Erectile Dysfunction
1 drug in this indication
Atrial Fibrillation
1 drug in this indication
Alzheimer's Disease
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Enuresis
1 drug in this indication
Pancreatic Neoplasms
1 drug in this indication
Gastroesophageal Reflux
1 drug in this indication
Essential Tremor
1 drug in this indication
recurrent or metastatic head and neck cancer
1 drug in this indication
Sprains and Strains
1 drug in this indication
Diabetic Peripheral Neuropathy
1 drug in this indication
SLE (Systemic Lupus Erythematosus)
1 drug in this indication
depression
1 drug in this indication
Leukemia, Nonlymphocytic, Acute
1 drug in this indication
plaque psoriasis in adults and adolescents
1 drug in this indication
relapsed/refractory multiple myeloma after at least one prior therapy
1 drug in this indication
over-the-counter treatment of pain
1 drug in this indication
plaque psoriasis
1 drug in this indication
Asthma
1 drug in this indication
newly diagnosed multiple myeloma (NDMM)
1 drug in this indication
axial psoriatic arthritis
1 drug in this indication
Arthralgia
1 drug in this indication
High-risk localized prostate cancer
1 drug in this indication
high-risk prostate cancer (perioperative treatment with ADT before and after surgery)
1 drug in this indication
psoriatic arthritis
1 drug in this indication
Sjögren's disease
1 drug in this indication
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
1 drug in this indication
Recurrent head and neck cancer after prior chemotherapy and immunotherapy
1 drug in this indication
head and neck cancer
1 drug in this indication
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
1 drug in this indication
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed on or after platinum-based chemotherapy
1 drug in this indication
Recurrent or metastatic head and neck cancer (second-line)
1 drug in this indication
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after progression on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody
1 drug in this indication
Advanced head and neck cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Johnson & Johnson's drug pipeline?→
CatalystAlert tracks 272 drug candidates in Johnson & Johnson's (JNJ) pipeline across Phase 3, Phase 2. Its lead program is Nipocalimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Johnson & Johnson's next FDA catalyst?→
Johnson & Johnson's (JNJ) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JNJ biotech catalysts?→
Add JNJ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Johnson & Johnson's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
